April 25, 2025 – A pivotal Phase III clinical trial published in The New England Journal of Medicine has demonstrated that a single oral dose of baloxavir marboxil (Xofluza®) in flu patients can reduce the risk of viral transmission to untreated household members by 32%. The CENTERSTONE study provides new scientific evidence for controlling influenza spread within families.
Influenza: A Persistent Global Health Challenge
As a major public health concern, influenza affects approximately 1 billion people annually, leading to millions of hospitalizations and hundreds of thousands of deaths worldwide. Research indicates that nearly one-third of flu transmissions occur within households, with workplace absenteeism among adults further exacerbating economic impacts. In the context of co-circulating respiratory illnesses, effective strategies to interrupt transmission chains remain critical.
Key Findings and Clinical Implications
While the study met its primary endpoint with statistically significant results, the secondary endpoint—measuring symptomatic transmission—did not reach statistical significance. Investigators suggest this may relate to sample size or observation period limitations but note a consistent trend toward reduced transmission risk. No new safety concerns were identified, aligning with the drug’s established profile.
Collaborative Research and Future Directions
The multinational study, conducted by a team of global researchers, has submitted its data to regulatory agencies for review. Experts recommend further investigations into age-specific and immunocompromised population responses, as well as expanded community-based applications to refine treatment protocols.
This breakthrough highlights baloxavir marboxil’s potential not only as a therapeutic but also as a transmission-blocking agent, marking a significant advancement in influenza management strategies.
Related topic:
